##common.pageHeaderLogo.altText##

Vol. 3 No. 3 (2023)

Emergencies in Hematology: Tumor Lysis Syndrome

Clinical Medicine And Health Research Journal, Vol. 3 No. 3 (2023), 5 June 2023 , Page 428-433
https://doi.org/10.18535/cmhrj.v3i3.183

Abstract

TLS (tumor lysis syndrome) is a serious consequence of haematologic malignancies and their treatment. The condition is defined by laboratory abnormalities alone (laboratory TLS) or in conjunction with clinical consequences such as renal failure, seizures, and arrhythmias (clinical TLS). Clinical TLS is a risk factor for increased morbidity and death in cancer patients, although it may be avoided. As a result, accurate prediction is crucial to the effective management of patients at risk for TLS, and it takes into account both disease characteristics (tumor kind and load) and patient factors (baseline renal insufficiency or hyperuricaemia). In low- and intermediate-risk individuals, water and allopurinol are used to prevent TLS, whereas rasburicase is used in high-risk patients.

Keywords:
  • tumor lysis syndrome, renal failure, leukemia,lymphoma.

How to Cite

Michail Michailidou, E. . (2023). Emergencies in Hematology: Tumor Lysis Syndrome. Clinical Medicine And Health Research Journal, 3(3), 428–433. https://doi.org/10.18535/cmhrj.v3i3.183

Download Citation

References

  • AbbVie Inc. (2018) Venclexta (venetoclax) [pack-age insert]. U.S. Food and Drug Administrationwebsite. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208573s009lbl.pdf.
  • Andreoli, S.P., Clark, J.H., McGuire, W.A. & Berg-stein, J.M. (1986) Purine excretion duringtumor lysis in children with acute lymphocyticleukemia receiving allopurinol: Relationship toacute renal failure.The Journal of Pediatrics,109,292–298.
  • Baeksgaard, L. & Sorensen, J.B. (2003) Acutetumor lysis syndrome in solid tumors–a casereport and review of the literature.Cancer Chemotherapy and Pharmacology,51, 187–92.
  • Baudon, C., Duhoux, F.P., Sinapi, I. & Canon, J.L.(2016) Tumor lysis syndrome followingtrastuzumab and pertuzumab for metastaticbreast cancer: a case report.Journal of MedicalCase Reports,10, 178.
  • Bosly, A., Sonet, A., Pinkerton, C.R., McCowage,G., Bron, D., Sanz, M.A. & van den Berg, H.(2003) Rasburicase (recombinant urate oxidase)for the management of hyperuricemia inpatients with cancer: report of an internationalcompassionate use study.Cancer,98, 1048–54.
  • Cairo, M.S. & Bishop, M. (2004) Tumour lysissyndrome: new therapeutic strategies and classi-fication.British Journal of Haematology,127,3–11.
  • Cairo, M.S., Gerrard, M., Sposto, R., Auperin, A.,Pinkerton, C.R., Michon, J., Weston, C., Per-kins, S.L., Raphael, M., McCarthy, K. & Patte,C. (2007) Results of a randomized internationalstudy of high-risk central nervous system Bnon-Hodgkin lymphoma and B acute lym-phoblastic leukemia in children and adolescents.Blood,109, 2736.
  • Cairo, M.S., Coiffier, B., Reiter, A., Younes, A.;TLS Expert Panel. (2010) Recommendations forthe evaluation of risk and prophylaxis oftumour lysis syndrome (TLS) in adults and chil-dren with malignant diseases: an expert TLSpanel consensus.British Journal of Haematology,149,578–586.
  • Caravaca-Fontan, F., Martinez-Saez, O., Pampa-Saico, S., Olmedo, M.E., Gomis, A. & Garrido,P. (2017) Tumor lysis syndrome in solidtumors: Clinical characteristics and prognosis.Medicina Clınica,148, 121–124.
  • Cheson, B.D., Heitner Enschede, S., Cerri, E.,Desai, M., Potluri, J., Lamanna, N. & Tam, C.(2017) Tumor lysis syndrome in chronicymphocytic leukemia with novel targetedagents.The Oncologist,22, 1283–1291
  • Coiffier, B., Altman, A., Pui, C.-H., Younes, A. &Cairo, M.S. (2008) Guidelines for the manage-ment of pediatric and adult tumor lysis syn-drome: an evidence-based review.Journal ofClinical Oncology,26, 2767–2778.
  • Davidson, M.B., Thakkar, S., Hix, J.K., Bhan-darkar, N.D., Wong, A. & Schreiber, M.J. (2004)Pathophysiology, clinical consequences, andtreatment of tumor lysis syndrome.The Ameri-can Journal of Medicine,116, 546–554.
  • Deconti, R.C. & Calabresi, P. (1966) Use of allop-urinol for prevention and control of hyper-uricemia in patients with neoplastic disease.New England Journal of Medicine,274,481–486.
  • DiNardo, C.D., Rausch, C.R., Benton, C., Kadia, T.,Jain, N., Pemmaraju, N., Daver, N., Covert, W.,Marx, K.R., Mace, M., Jabbour, E., Cortes, J.,Garcia-Manero, G., Ravandi, F., Bhalla, K.N.,Kantarjian, H. & Konopleva, M. (2018) Clinicalexperience with the BCL2-inhibitor venetoclax incombination therapy for relapsed and refractoryacute myeloid leukemia and related myeloidmalignancies.American Journal of Hematology,93, 401–407.
  • DiNardo, C.D., Pratz, K., Pullarkat, V., Jonas,B.A., Arellano, M., Becker, P.S., Frankfurt, O.,Konopleva, M., Wei, A.H., Kantarjian, H.M.,Xu, T., Hong, W.J., Chyla, B., Potluri, J., Pol-lyea, D.A. & Letai, A. (2019) Venetoclax com-bined with decitabine or azacitidine intreatment-naive, elderly patients with acute mye-loid leukemia.Blood,133,7–17.
  • Durani, U., Shah, N.D. & Go, R.S. (2017) In-hos-pital outcomes of tumor lysis syndrome: a pop-ulation-based study using the national inpatientsample.The Oncologist,22, 1506–1509.Frei, E. III, Bentzel, C.J., Rieselbach, R. & Block,J.B. (1963) Renal complications of neoplasticdisease.Journal of Chronic Diseases,16, 757–758.
  • Goldman, S.C., Holcenberg, J.S., Finklestein, J.Z.,Hutchinson, R., Kreissman, S., Johnson, F.L., Tou,C., Harvey, E., Morris, E. & Cairo, M.S. (2001) Arandomized comparison between rasburicase andallopurinol in children with lymphoma or leuke-mia at high risk for tumor lysis.Blood,97, 2998.ten
  • Harkel, A.D., Kist-Van Holthe, J.E., Van Weel,M. & Van Der Vorst, M.M. (1998) Alkaliniza-tion and the tumor lysis syndrome.Medical andPediatric Oncology,31,27–8.
  • Hillmen, P., Rawstron, A.C., Brock, K., Mu~noz-Vicente, S., Yates, F.J., Bishop, R., Boucher, R.,Macdonald, D., Fegan, C., McCaig, A., Schuh,A., Pettitt, A., Gribben, J.G., Patten, P.E.M.,Devereux, S., Bloor, A., Fox, C.P., Forconi, F. &Munir, T. (2019) Ibrutinib plus venetoclax inrelapsed/refractory chronic lymphocytic leuke-mia: the CLARITY study.Journal of ClinicalOncology,37, 2722–2729.
  • Hochberg, J. & Cairo, M.S. (2008) Tumor lysissyndrome: current perspective.Haematologica,93,9.Holland, P. & Holland, N.H. (1968) Preventionand management of acute hyperuricemia inchildhood leukemia.The Journal of Pediatrics,72, 358–366.
  • Howard, S.C., Jones, D.P. & Pui, C.-H. (2011) Thetumor lysis syndrome.New England Journal ofMedicine,364, 1844–1854.Huang, K., Brenner, W. & Prasad, V. (2019)Tumor lysis syndrome: a rare but serious com-plication of radioligand therapies.Journal ofNuclear Medicine,60, 752–755.
  • Huzmeli, C., Eliacik, E., Saglam, M., Doner, B. &Candan, F. (2016) Spontaneous tumour lysissyndrome in a multiple myeloma.Case Reportsin Medicine,2016, 9620520.
  • Jeha, S., Kantarjian, H., Irwin, D., Shen, V., She-noy, S., Blaney, S., Camitta, B. & Pui, C.H.(2004) Efficacy and safety of rasburicase, arecombinant urate oxidase (ElitekTM), in themanagement of malignancy-associated hyper-uricemia in pediatric and adult patients: finalresults of a multicenter compassionate use trial.Leukemia,19, 34.Jones, D.P., Mahmoud, H. & Chesney, R.W.(1995) Tumor lysis syndrome: pathogenesis andmanagement.Pediatric Nephrology (Berlin, Ger-many),9, 206–12.
  • van Kalleveen, M.W., Walraven, M. & Hendriks,M.P. (2018) Pazopanib-related tumor lysis syn-drome in metastatic clear cell renal cell carci-noma: a case report.Investigational New Drugs,36, 513–516.
  • Kater, A.P., Kersting, S., van Norden, Y., Dubois,J., Dobber, J.A., Mellink, C.H., Evers, L.M.,Croon-de Boer, F., Schreurs, J., Van Der Spek,E., Visser, H., Idink, C., Wittebol, S., Hoogen-doorn, M., Tonino, S.H., Mobasher, M. &Levin,M.D. (2018) Obinutuzumab pretreatment abro-gates tumor lysis risk while maintaining unde-tectable MRD for venetoclax + obinutuzumabin CLL.Blood Advances,2, 3566–3571.
  • Kravitz, S.C., Diamond, H.D. & Craver, L.F.(1951) Uremia complicating leukemiachemotherapy: report of a case treated with tri-ethylene melamine.Journal of the AmericanMedical Association,146, 1595–1597.
  • Mato,A.R.,Riccio,B.E.,Qin,L.,Heitjan,D.F.,Car-roll, M., Loren, A., Porter, D.L., Perl, A., Stadt-mauer, E., Tsai, D., Gewirtz, A. & Luger, S.M.(2006) A predictive model for the detection oftumor lysis syndrome during AML induction ther-apy.Leukaemia & Lymphoma,47,877–83.
  • Montesinos, P., Lorenzo, I., Martin, G., Sanz, J.,Perez-Sirvent, M.L., Martinez, D., Orti, G.,Algarra, L., Martinez, J., Moscardo, F., de laRubia, J., Jarque, I., Sanz, G. & Sanz, M.A.(2008) Tumor lysis syndrome in patients withacute myeloid leukemia: identification of riskfactors and development of a predictive model.Haematologica,93,67–74.
  • Mylan Pharmaceuticals. (2018) Zyloprim (allopuri-nol) [package insert]. U.S. Food and DrugAdministration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016084s044lbl.pdf.Okamoto, K., Kinoshita, T., Shimizu, M., Okura,I., Kawada, A., Mizobuchi, K. & Ando, M.(2015) A case of spontaneous tumor lysis syn-drome in a patient with ovarian cancer.CaseReports in Obstetrics and Gynecology,2015,461870.
  • Opyrchal, M., Figanbaum, T., Ghosh, A., Rajku-mar, V. & Caples, S. (2010) Spontaneous tumorlysis syndrome in the setting of B-cell lym-phoma.Case Reports in Medicine,2010, 610969.Pui, C.H. (2002) Rasburicase: a potent uricolyticagent.Expert Opinion on Pharmacotherapy,3,433–42.
  • Pui, C.H., Jeha, S., Irwin, D. & Camitta, B.(2001a) Recombinant urate oxidase (rasburicase)in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adultpatients: results of a compassionate-use trial.Leukemia,15, 1505–1509.
  • Pui, C.H., Mahmoud, H.H., Wiley, J.M., Woods,G.M., Leverger, G., Camitta, B., Hastings, C.,Blaney, S.M., Relling, M.V. & Reaman, G.H.(2001b) Recombinant urate oxidase for the pro-phylaxis or treatment of hyperuricemia inpatients With leukemia or lymphoma.Journal ofClinical Oncology,19, 697–704.
  • Relling, M.V., McDonagh, E.M., Chang, T., Cau-dle, K.E., McLeod, H.L., Haidar, C.E., Klein, T.& Luzzatto, L. (2014) Clinical PharmacogeneticsImplementation Consortium (CPIC) guidelinesfor rasburicase therapy in the context of G6PDdeficiency genotype.Clinical Pharmacology &Therapeutics,96, 169–174.
  • Riccio, B., Mato, A., Olson, E.M., Berns, J.S. &Luger, S. (2006) Spontaneous tumor lysis syn-drome in acute myeloid leukemia: two cases anda review of the literature.Cancer Biology &Therapy,5, 1614–1617.
  • Richmond, G.H. & Beardsley, G.D. (1953) Nitro-gen mustard therapy complicated by acute renalfailure due to uric acid crystallization.Annals ofInternal Medicine,39, 1327–1332.
  • Roberts, A.W., Davids, M.S., Pagel, J.M., Kahl,B.S., Puvvada, S.D., Gerecitano, J.F., Kipps, T.J.,Anderson, M.A., Brown, J.R., Gressick, L.,Wong, S., Dunbar, M., Zhu, M., Desai, M.B.,Cerri, E., Heitner Enschede, S., Humerickhouse,R.A., Wierda, W.G. & Seymour, J.F. (2016) Tar-geting BCL2 with venetoclax in relapsed chroniclymphocytic leukemia.New England Journal ofMedicine,374, 311–322.
  • Sanofi-Aventis. (2009) U.S. LLC. Elitek (rasburic-ase) [package insert]. U.S. Food and DrugAdministration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103946s5083lbl.
  • Shimada, M., Johnson, R.J., May, W.S. Jr, Linge-gowda, V., Sood, P., Nakagawa, T., Van, Q.C.,Dass, B., Ejaz, A.A. (2009) A novel role for uricacid in acute kidney injury associated withtumour lysis syndrome.Nephrology DialysisTransplantation,24, 2960–2964.
  • Spina, M., Grosicki, S., Glushko, N.L., Ristic, D.,Jakucs, J., Montesinos, P., Mayer, J., Rego, E.M.,Capriati, A., Simonelli, C., Maggi, C.A., Baldini,S., Scartoni, S., Nagy, Z., Ribera, J.M., Federico,M., Aurer, I., Jordan, K., Borsaru, G., Pristupa
    • Article Viewed: 0 Total Download

    ##plugins.themes.ojsPlusA.frontend.article.downloadstatastics##

    Cover Image

    Information